Literature DB >> 24091204

Universal anti-neuraminidase antibody inhibiting all influenza A subtypes.

Tracey M Doyle1, Anwar M Hashem, Changgui Li, Gary Van Domselaar, Louise Larocque, Junzhi Wang, Daryl Smith, Terry Cyr, Aaron Farnsworth, Runtao He, Aeron C Hurt, Earl G Brown, Xuguang Li.   

Abstract

The only universally conserved sequence amongst all influenza A viral neuraminidase (NA) is located between amino acids 222-230 and plays crucial roles in viral replication. However, it remained unclear as to whether this universal epitope is exposed during the course of infection to allow binding and inhibition by antibodies. Using a monoclonal antibody (MAb) targeting this specific epitope, we demonstrated that all nine subtypes of NA were inhibited in vitro by the MAb. Moreover, the antibody also provided heterosubtypic protection in mice challenged with lethal doses of mouse-adapted H1N1 and H3N2, which represent group I and II viruses, respectively. Furthermore, we report amino acid residues I222 and E227, located in close proximity to the active site, are indispensable for inhibition by this antibody. This unique, highly-conserved linear sequence in viral NA could be an attractive immunological target for protection against diverse strains of influenza viruses. Crown
Copyright © 2013. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cross-protection; Neuraminidase; Universal antibody

Mesh:

Substances:

Year:  2013        PMID: 24091204     DOI: 10.1016/j.antiviral.2013.09.018

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  54 in total

1.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.

Authors:  Nancy J Cox; Julian Hickling; Rebecca Jones; Guus F Rimmelzwaan; Linda C Lambert; John Boslego; Larisa Rudenko; Leena Yeolekar; James S Robertson; Joachim Hombach; Justin R Ortiz
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

Review 3.  Influenza virus antigenicity and broadly neutralizing epitopes.

Authors:  Gillian M Air
Journal:  Curr Opin Virol       Date:  2015-04-04       Impact factor: 7.090

Review 4.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

Review 5.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

6.  Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.

Authors:  Maryna C Eichelberger; Arnold S Monto
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

7.  Double-Layered M2e-NA Protein Nanoparticle Immunization Induces Broad Cross-Protection against Different Influenza Viruses in Mice.

Authors:  Ye Wang; Lei Deng; Gilbert X Gonzalez; Latika Luthra; Chunhong Dong; Yao Ma; Jun Zou; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Adv Healthc Mater       Date:  2019-12-15       Impact factor: 9.933

8.  Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Authors:  Ki-Hye Kim; Yu-Jin Jung; Youri Lee; Bo Ryoung Park; Judy Oh; Yu-Na Lee; Min-Chul Kim; Subbiah Jeeva; Sang-Moo Kang
Journal:  Virology       Date:  2020-08-22       Impact factor: 3.616

9.  Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.

Authors:  Lianlian Jiang; Giovanna Fantoni; Laura Couzens; Jin Gao; Ewan Plant; Zhiping Ye; Maryna C Eichelberger; Hongquan Wan
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

10.  Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection.

Authors:  Hongquan Wan; Li Qi; Jin Gao; Laura K Couzens; Lianlian Jiang; Yamei Gao; Zong-Mei Sheng; Sharon Fong; Megan Hahn; Surender Khurana; Jeffery K Taubenberger; Maryna C Eichelberger
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.